Observational studyBlood cancer journal2025
Whole body MRI by MY-RADS for imaging response assessment in multiple myeloma.
Observational study in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02403102 (Imageguided Theranostics in Multiple Myeloma), which is not on this map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Imageguided Theranostics in Multiple Myeloma
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Whole-body MRI for staging and follow-up of primary musculoskeletal tumours: a systematic review.The British journal of radiology · 2026Pooled it
- [Imaging in monoclonal plasma cell disorders : Multiple myeloma, smouldering multiple myeloma and MGUS].Radiologie (Heidelberg, Germany) · 2026Review
- AI-derived whole-body MRI metrics in patients with multiple myeloma reveal unique insights into body composition and outcomes.Blood advances · 2026Observational
- Diffusion-Weighted Imaging in the Musculoskeletal System: Evolving Role in Modern Imaging Practice.Diagnostics (Basel, Switzerland) · 2026Review
- Bibliometric Analysis of Whole-Body MRI from 2015 to 2025 Across Clinical Applications, Quantitative Imaging, and Artificial Intelligence.Journal of imaging · 2026Article
- Clinical implications of minimal residual disease monitoring in multiple myeloma.International journal of hematology · 2026Review
- Predictive imaging biomarkers on whole-body diffusion-weighted MRI (WB-DWMRI) and [Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Precision medicine in myeloma demands precision imaging: is whole body MRI the solution?Cancer imaging : the official publication of the International Cancer Imaging Society · 2026Article
- Article
- Shaping the future of multiple myeloma with artificial intelligence and digital twins: from concept to clinic.Frontiers in digital health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Minimal residual disease (MRD) testing has underpinned the evaluation and expansion of therapeutic options for patients with multiple myeloma (MM). Imaging is essential for evaluating residual disease status, overcoming sampling errors inherent with other MRD modalities. The accuracy of whole-body MRI (WB-MRI) has led to its incorporation into MM diagnostic imaging guidelines. We report here on the prospective iTIMM trial (image-guided theranostics in MM; NCT02403102), designed to evaluate imaging residual disease using contemporary, functional WB-MRI as per MY-RADS protocol. In iTIMM, 70 MM patients planned to undergo autologous stem cell transplantation ASCT in newly diagnosed MM or at first relapse, underwent WB-MRI before start of induction and at day 100 post-ASCT. Patients with residual disease post-ASCT (RAC2 or higher) had shorter progression-free survival (median 24 months, 95% confidence interval (CI): 19-41 vs. 42 months, 95% CI: 37-not evaluable (NE), log-rank p = 0.013; hazard ratio (HR) 2.09 (95% CI: 1.15-3.78) and overall survival (median 47 months, 95% CI: 30.9-NE vs. NE (95% CI: NE-NE), p = 0.002, HR = 5.45 (95% CI: 1.67-17.87) than those without (RAC1). Imaging response also refined the prognostic association of bone marrow MRD and serological response. Our results support WB-MRI implementation for evaluation of residual disease alongside conventional laboratory-based assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.